71302-71-1

Basic information

• Product Name: 5-PYRROLIDINOAMYLAMINE
• Synonyms: 5-PYRROLIDINOAMYLAMINE;5-(pyrrolidin-1-yl)pentan-1-aMine;5-(Pyrrolidin-1-yl)pentylamine;1-PyrrolidinepentanaMine 2HCl
• CAS NO: 71302-71-1
• Molecular Formula: C₉H₂₀N₂
• Molecular Weight: 156.27
• Mol File: 71302-71-1.mol

Chemical Properties

• Boiling Point: 233.0±8.0℃ (760 Torr)
• Flash Point: 88.7±13.6℃
• Appearance: /
• Density: 0.916±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 0.0572mmHg at 25°C
• Refractive Index: 1.483
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 5-PYRROLIDINOAMYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-PYRROLIDINOAMYLAMINE(71302-71-1)
• EPA Substance Registry System: 5-PYRROLIDINOAMYLAMINE(71302-71-1)

Safety Data

• Hazardous Substances Data: 71302-71-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
5-PYRROLIDINOAMYLAMINE is used as a research chemical for studying the effects of stimulants on the central nervous system. Its properties can provide insights into the development of new medications for various conditions, such as attention deficit hyperactivity disorder (ADHD) and narcolepsy.
Used in Forensic Toxicology:
In forensic toxicology, 5-PYRROLIDINOAMYLAMINE is used as a reference compound for identifying and analyzing substances in biological samples. Its presence in samples can indicate the abuse of controlled substances and contribute to the investigation of drug-related crimes.
Used in Drug Testing and Detection:
5-PYRROLIDINOAMYLAMINE is used in drug testing and detection methods to screen for the presence of this controlled substance in individuals suspected of drug abuse. Its identification in urine, blood, or hair samples can confirm the use of this stimulant and support legal actions or treatment programs.
Used in Regulatory Compliance:
In industries where the use and distribution of controlled substances are strictly regulated, 5-PYRROLIDINOAMYLAMINE is used as a reference material for ensuring compliance with legal standards. Its detection in products or manufacturing processes can trigger investigations and enforcement actions to protect public health and safety.

InChI:InChI=1/C9H20N2/c10-6-2-1-3-7-11-8-4-5-9-11/h1-10H2

Upstream product

• 71888-57-8 5-(pyrrolidin-1-yl)-pentanenitrile 
• 954-81-4 N-(5-bromopentyl)phthalimide 
• 111-24-0 1,5-dibromo-pentane 
• 928006-41-1 2-(5-(pyrrolidin-1-yl)pentyl)isoindoline-1,3-dione 

Downstream Products

• 928006-44-4 KYS₀₅₀₇₆ 
• 928006-46-6 {2-[methyl-(5-pyrrolidin-1-yl-pentyl)-amino]-3-phenyl-3,4-dihydro-quinazolin-4-yl}-acetic acid 
• 928006-45-5 KYS₀₅₀₇₉ 
• 928006-47-7 {3-biphenyl-4-yl-2-[methyl-(5-pyrrolidin-1-yl-pentyl)-amino]-3,4-dihydro-quinazolin-4-yl}-acetic acid 
• 1620401-82-2 6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine 
• 1620401-83-3 6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine trifluoroacetic acid 

Relevant articles and documents

Novel Multitarget Directed Triazinoindole Derivatives as Anti-Alzheimer Agents

The multifaceted nature of Alzheimer's disease (AD) demands treatment with multitarget-directed ligands (MTDLs) to confront the key pathological aberrations. A novel series of triazinoindole derivatives were designed and synthesized. In vitro studies revealed that all the compounds showed moderate to good anticholinesterase activity; the most active compound 23e showed an IC50 value of 0.56 ± 0.02 μM for AChE and an IC50 value of 1.17 ± 0.09 μM for BuChE. These derivatives are also endowed with potent antioxidant activity. To understand the plausible binding mode of the compound 23e, molecular docking studies and molecular dynamics simulation studies were performed, and the results indicated significant interactions of 23e within the active sites of AChE as well as BuChE. Compound 23e successfully diminished H2O2-induced oxidative stress in SH-SY5Y cells and displayed excellent neuroprotective activity against H2O2 as well as Aβ-induced toxicity in SH-SY5Y cells in a concentration dependent manner. Furthermore, it did not show any significant toxicity in neuronal SH-SY5Y cells in the cytotoxicity assay. Compound 23e did not show any acute toxicity in rats at doses up to 2000 mg/kg, and it significantly reversed scopolamine-induced memory deficit in mice model. Additionally, compound 23e showed notable in silico ADMET properties. Taken collectively, these findings project compound 23e as a potential balanced MTDL in the evolution process of novel anti-AD drugs.

3,4-DIHYDROQUINAZOLINE DERIVATIVES

The present invention relates to 3,4-dihydroquinazoline derivatives, a process of preparing them and a pharmaceutical composition including them. The 3,4-dihydroquinazoline derivatives of the present invention have excellent T-type calcium channel blocking effect and anti-cancer activity.

Synthesis and biological evaluation of novel T-type calcium channel blockers

3,4-Dihydroquinazoline analogues substituted by N-methyl-N-(5-pyrrolidinopentyl)amine at the 2-position were synthesized and their blocking effects were evaluated for T- and N-type calcium channels. Compound 11b (KYS05080), compared to mibefradil (IC50 = 1.34 ± 0.49 μM), was about 5-fold potent (IC50 = 0.26 ± 0.01 μM) for T-type calcium channel (α1G) blocking and its selectivity of T/N-type was also improved (7.5 versus 1.4 of mibefradil).

SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL) BENZOHETEROARYL COMPOUNDS

This invention is directed to an (aminoiminomethyl or aminomethyl) benzoheteroaryl compound of formula I which is useful for inhibiting the activity of Factor Xa by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.